Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.72 |
| ▸ | NPC1 | O15118 | 4/20 | 0.72 |
| ▸ | RAB9A | P51151 | 4/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892914 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL70743 | 0.83 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL9852328 | 0.81 | SMN1; SMN2 (0.73) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL9852174 | 0.79 | ADORA3 (0.77) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL222738 | 0.78 | PARP1 (0.82) | NPC1RAB9AHTTMEN1KMT2A | |
| SCHEMBL16254958 | 0.77 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL4166912 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL4153007 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL70693 | 0.75 | CCNE1 (0.63) | SMN1; SMN2NPC1RAB9ALMNAALDH1A1 | |
| SCHEMBL4159170 | 0.74 | ADORA3 (0.61) | SMN1; SMN2NPC1RAB9AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| CN-102036558-A | Novel piperidine derivatives as stearoyl-CoA desaturase inhibitors | FOREST LAB HOLDINGS LTD | 2011-04-27 | — | — | CN | disclosed |
| EP-2268143-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | Forest Laboratories Holdings Limited (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | SMN1; SMN2 3937/4885NPC1 201/4885RAB9A 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.